JP7781764B2 - ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用 - Google Patents

ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用

Info

Publication number
JP7781764B2
JP7781764B2 JP2022554833A JP2022554833A JP7781764B2 JP 7781764 B2 JP7781764 B2 JP 7781764B2 JP 2022554833 A JP2022554833 A JP 2022554833A JP 2022554833 A JP2022554833 A JP 2022554833A JP 7781764 B2 JP7781764 B2 JP 7781764B2
Authority
JP
Japan
Prior art keywords
bcma
subject
nirogacestat
dihydrobromide
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022554833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517243A (ja
JP2023517243A5 (enExample
Inventor
トッド ウェブスター シアラー，
バドレディン エドゥリス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SpringWorks Therapeutics Inc
Original Assignee
SpringWorks Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SpringWorks Therapeutics Inc filed Critical SpringWorks Therapeutics Inc
Publication of JP2023517243A publication Critical patent/JP2023517243A/ja
Publication of JP2023517243A5 publication Critical patent/JP2023517243A5/ja
Priority to JP2025139609A priority Critical patent/JP2025168430A/ja
Application granted granted Critical
Publication of JP7781764B2 publication Critical patent/JP7781764B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
JP2022554833A 2020-03-13 2021-03-12 ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用 Active JP7781764B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025139609A JP2025168430A (ja) 2020-03-13 2025-08-25 ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062989372P 2020-03-13 2020-03-13
US62/989,372 2020-03-13
PCT/US2021/022177 WO2021183934A1 (en) 2020-03-13 2021-03-12 A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025139609A Division JP2025168430A (ja) 2020-03-13 2025-08-25 ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用

Publications (3)

Publication Number Publication Date
JP2023517243A JP2023517243A (ja) 2023-04-24
JP2023517243A5 JP2023517243A5 (enExample) 2024-03-21
JP7781764B2 true JP7781764B2 (ja) 2025-12-08

Family

ID=75396879

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022554833A Active JP7781764B2 (ja) 2020-03-13 2021-03-12 ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用
JP2025139609A Pending JP2025168430A (ja) 2020-03-13 2025-08-25 ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025139609A Pending JP2025168430A (ja) 2020-03-13 2025-08-25 ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用

Country Status (17)

Country Link
US (1) US20230121547A1 (enExample)
EP (1) EP4132515B1 (enExample)
JP (2) JP7781764B2 (enExample)
KR (1) KR20230009873A (enExample)
CN (2) CN115916188A (enExample)
AR (1) AR121566A1 (enExample)
AU (1) AU2021236340A1 (enExample)
BR (1) BR112022018251A2 (enExample)
CA (1) CA3171267A1 (enExample)
CL (1) CL2022002479A1 (enExample)
CO (1) CO2022014388A2 (enExample)
IL (1) IL296075A (enExample)
MX (1) MX2022011258A (enExample)
PE (1) PE20230614A1 (enExample)
TW (1) TW202200132A (enExample)
WO (1) WO2021183934A1 (enExample)
ZA (1) ZA202209989B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024002590A (es) 2021-09-01 2024-03-22 Springworks Therapeutics Inc Sintesis de nirogacestat.
WO2023064872A1 (en) * 2021-10-14 2023-04-20 Precision Biosciences, Inc. Combinations of anti-bcma car t cells and gamma secretase inhibitors
CN118338900A (zh) * 2021-11-05 2024-07-12 斯普林渥克斯治疗有限公司 含尼罗加司他的组合物和治疗
MX2024005453A (es) * 2021-11-05 2024-07-22 Springworks Therapeutics Inc Composiciones y tratamientos con nirogacestat.
EP4436958A1 (en) * 2021-11-23 2024-10-02 Teva Pharmaceuticals International GmbH Solid state forms of nirogacestat salts
US11951096B2 (en) 2022-05-20 2024-04-09 Springworks Therapeutics, Inc. Treatments with nirogacestat
US12138246B2 (en) 2022-05-20 2024-11-12 Springworks Therapeutics, Inc. Treatments with nirogacestat
IL316750A (en) 2022-05-20 2025-01-01 Springworks Therapeutics Inc Treatments with Nirogesstat
US12667555B2 (en) 2022-05-20 2026-06-30 Springworks Therapeutics, Inc. Treatment of ovarian cancer with nirogacestat
US12036207B2 (en) 2022-05-20 2024-07-16 Springworks Therapeutics, Inc. Treatments with nirogacestat
JP2026508907A (ja) * 2023-03-09 2026-03-13 ▲蘇▼州科睿思制▲葯▼有限公司 ニロガセスタット二臭化水素酸塩の結晶形、及びその調製方法並びに用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018201501A1 (zh) 2017-05-05 2018-11-08 华为技术有限公司 一种辅助数据传输方法、设备及系统
JP7608435B2 (ja) 2019-08-09 2025-01-06 ファイザー・インク （ｓ）－２－（（（ｓ）－６，８－ジフルオロ－１，２，３，４－テトラヒドロナフタレン－２－イル）アミノ）－ｎ－（１－（２－メチル－１－（ネオペンチルアミノ）プロパン－２－イル）－１ｈ－イミダゾール－４－イル）ペンタンアミドの固体状態形態およびその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015120065A1 (en) * 2014-02-05 2015-08-13 The Trustees Of Columbia University In The City Of New York Gamma-secretase inhibition reduce apoc3 levels and plasma triglycerides
EP3324965A4 (en) * 2015-07-24 2019-07-03 Oncotracker, Inc. Gamma secretase modulators for the treatment of immune system dysfunction
IL268349B2 (en) * 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP3615068A1 (en) * 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) * 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
AU2018359907A1 (en) * 2017-11-06 2020-05-07 Fred Hutchinson Cancer Center Combination of a cell therapy and a gamma secretase inhibitor
US11970542B2 (en) * 2017-11-08 2024-04-30 Fred Hutchinson Cancer Center Bispecific antibodies specific for treating hematological malignancies
WO2019143818A1 (en) * 2018-01-17 2019-07-25 Mingsight Pharmaceuticals, Inc. Combination therapy for the treatment of cancer
BR112020023975A2 (pt) * 2018-05-24 2021-02-23 Ayala Pharmaceuticals Inc. composições que compreendem os compostos de bisfluoroalquil-1,4-benzodiazepinona e imunoterapêuticos e métodos de uso das mesmas
PE20210320A1 (es) * 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
MX2021012407A (es) * 2019-04-10 2021-11-12 Glaxosmithkline Ip Dev Ltd Terapia de combinacion con un anticuerpo anti bcma y un inhibidor de gamma secretasa.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018201501A1 (zh) 2017-05-05 2018-11-08 华为技术有限公司 一种辅助数据传输方法、设备及系统
JP7608435B2 (ja) 2019-08-09 2025-01-06 ファイザー・インク （ｓ）－２－（（（ｓ）－６，８－ジフルオロ－１，２，３，４－テトラヒドロナフタレン－２－イル）アミノ）－ｎ－（１－（２－メチル－１－（ネオペンチルアミノ）プロパン－２－イル）－１ｈ－イミダゾール－４－イル）ペンタンアミドの固体状態形態およびその使用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BLOOD[ONLINE]，2019年11月，VOL:134,NO:SUPPL.1，PAGE(S):1-2
Developmental Biology，2019年06月01日，Vol.453, No.2，p155-167，doi:10.1016/j.ydbio.2019.05.016
Journal of Clinical Oncology，Vol.33, No.15, suppl.，2015年05月20日，p1068，https://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.1068
Molecular Cancer Therapeutics，2010年06月08日，Vol.9, No.6，p1618-1628，doi:10.1158/1535-7163.MCT-10-0034
Patric Stahly，医薬品の塩選択、結晶多形のスクリーニングの重要性について，薬剤学，2006年，Vol.66，No.6，p.435-439
高田則幸，創薬段階における原薬Formスクリーニングと選択，PHARM STAGE，Vol. 6, No. 10，2007年01月15日，p. 20-25

Also Published As

Publication number Publication date
CN115916188A (zh) 2023-04-04
JP2023517243A (ja) 2023-04-24
KR20230009873A (ko) 2023-01-17
MX2022011258A (es) 2023-01-11
CO2022014388A2 (es) 2023-02-16
CA3171267A1 (en) 2021-09-16
WO2021183934A1 (en) 2021-09-16
BR112022018251A2 (pt) 2022-11-08
ZA202209989B (en) 2025-12-17
TW202200132A (zh) 2022-01-01
EP4132515B1 (en) 2026-08-05
JP2025168430A (ja) 2025-11-07
IL296075A (en) 2022-11-01
CN122272572A (zh) 2026-06-26
US20230121547A1 (en) 2023-04-20
AU2021236340A1 (en) 2022-09-29
CL2022002479A1 (es) 2023-08-18
AR121566A1 (es) 2022-06-15
PE20230614A1 (es) 2023-04-14
EP4132515A1 (en) 2023-02-15

Similar Documents

Publication Publication Date Title
JP2025168430A (ja) ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用
KR102944213B1 (ko) 2-(2,6-디옥소피페리딘-3-일)-4-((2-플루오로-4-((3-모르폴리노아제티딘-1-일)메틸)벤질)아미노)이소인돌린-1,3-디온을 사용하여 비-호지킨 림프종을 치료하는 방법
EP3601258A1 (en) Substituted isoquionline derivatives as immunomudulators
JP7262100B2 (ja) 長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化
AU2020369497C1 (en) Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione
BR112012020142A2 (pt) moduladores do receptor de nmda com estrutura secundária estabilizada e usos dos mesmos.
US20250263487A1 (en) Methods to manipulate alpha-fetoprotein (afp)
JP2020522473A (ja) Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質
MX2010012231A (es) Inmunomodulacion mediante inhibidores iap.
JP2020504086A (ja) ヒストン脱アセチル化酵素阻害剤とｃｄ３８阻害剤とを含む医薬組み合わせ物及びその使用方法
TW201815417A (zh) Ｐｄ－１抗體與ｉｄｏ抑制劑聯合在製備抗腫瘤的藥物中的用途
US11872220B2 (en) Methods and compositions for treating B-cell malignancies
CA2914501C (en) Compositions and methods for reducing or preventing metastasis
JPH06503344A (ja) 可溶性の補体受容体と、補体を抑制しかつ／または免疫活性を抑制する化合物との相乗組成物
US20240100159A1 (en) Use of il-7r-alpha-gamma agonist peptides in cell manufacturing
EA051675B1 (ru) Комбинированная терапия с нирогацестатом и bcma-направленной терапией и ее применение
TWI843159B (zh) 藥物組合及其應用
IL324452A (en) Alternative phenyl oxazolone compounds
KR20170109541A (ko) 알파9 인테그린 길항제를 사용한 골수 줄기 세포 니치로부터의 hsc의 이탈 및 방출
CN1786024A (zh) 藻红蛋白、晶体生产工艺及制品
CN115947848A (zh) Dc细胞和单克隆抗体制备的抗癌组合物
US20250122241A1 (en) Cyclic peptide immunomodulators
JP2026509438A (ja) ポルフィリン及びその薬学的使用
Schriber et al. Post Transplant Cytoxan in Patients over the Age of 60 Undergoing Allogeneic Transplant: Less Graft Versus Host Disease (GVHD) Related Deaths Than in Patients Treated with Standard Tacrolimus Methotrexate
Borai Hanan Mohammed Mohammed El shershaby.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250325

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250825

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251031

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251126

R150 Certificate of patent or registration of utility model

Ref document number: 7781764

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150